Lower Mortality Risk Seen With Statin Use in Older Men

This article originally appeared here.
Share this content:
Lower Mortality Risk Seen With Statin Use in Older Men
Lower Mortality Risk Seen With Statin Use in Older Men

FRIDAY, Sept. 15, 2017 (HealthDay News) -- Statin use is associated with a significantly lower risk of mortality in older male physicians, and a non-significant lower risk of cardiovascular disease (CVD) events, according to a study published online Sept. 11 in the Journal of the American Geriatrics Society.

Ariela R. Orkaby, M.D., from the Massachusetts Veterans Epidemiology and Research Information Center in Boston, and colleagues analyzed data from a prospective cohort of participants in the Physicians' Health Study (7,213 male physicians ≥70 years without a history of CVD) over a median of seven years of follow-up. Non-statin users were propensity matched to 1,130 statin users.

The researchers found that over the study period statin use was associated with an 18 percent lower risk of all-cause mortality (hazard ratio [HR], 0.82; 95 percent confidence interval [CI], 0.69 to 0.98) and non-significantly lower risk of CVD events (HR, 0.86; 95 percent CI, 0.70 to 1.06) and stroke (HR, 0.70; 95 percent CI, 0.45 to 1.09). Results did not change according to age group at baseline (70 to 76 years or >76 years) or functional status. For those with elevated cholesterol, statin users had fewer major CVD events than non-users (HRs, 0.68 [95 percent CI, 0.50 to 0.94] and 1.43 [95 percent CI, 0.99 to 2.07], respectively).

"Further work is needed to determine which older individuals will benefit from statins as primary prevention," the authors write.

Several authors report financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »